Intelligence · Clinical Development
Pipeline search results
Programs matching “selinexor” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 59 pipeline programs matching "selinexor" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Selinexor
Karyopharm Therapeutics Inc
Locally Advanced Unresectable or Metastatic Melanoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Metastatic Colorectal Cancer
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Multiple Myeloma, Refractory
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Myelodysplastic Syndrome
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Myeloma Multiple
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Non-small Cell Lung Cancer
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Ovarian Carcinoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Primary Myelofibrosis
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Prostate Cancer
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Recurrent Small Cell Lung Carcinoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Smoldering Multiple Myeloma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Solid Tumor Malignancy
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Relapsed and Refractory Multiple Myeloma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Breast Cancer
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Coronavirus Infection
2 trials -
Selinexor
Karyopharm Therapeutics Inc
Diabetic Foot Ulcers
1 trial -
Selinexor (KPT-330)
Karyopharm Therapeutics Inc
Squamous Cell Carcinoma
1 trial -
Selinexor 100 mg
Karyopharm Therapeutics Inc
Non-Small Cell Lung Carcinoma (NSCLC)
1 trial -
Selinexor 20 MG Oral Tablet
Karyopharm Therapeutics Inc
Multiple Myeloma
1 trial -
Selinexor 60 MG
Karyopharm Therapeutics Inc
Multiple Myeloma
1 trial -
Selinexor 60 mg
Karyopharm Therapeutics Inc
Myelofibrosis
1 trial -
selinexor
Karyopharm Therapeutics Inc
Richter's Transformation
1 trial -
selinexor (KPT-330)
Karyopharm Therapeutics Inc
Myelodysplastic Syndromes
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.